Changes in tear function and the ocular surface after topical XXXX treatment for @entity56 : an open-label study.

@entity1 @entity267 @entity202 @entity13205 @entity1544 @entity56 @entity941 @entity121
BACKGROUND: @entity13205 0.1% eye drops represent a new class of anti-allergic agent with combined antihistaminic and mast cell-stabilizing properties. OBJECTIVE: The purpose of this study was to describe alterations in tear function and the ocular surface in @entity1 with @entity56 and to analyze the effect of topical @entity13205 treatment on corneal sensitivity, tear function, and impression cytology variables. METHODS: This was a single-center, 3-visit, prospective, open-label study conducted in @entity1 with @entity56 . @entity1 received 1 drop of topical @entity13205 0.1% BID for 3 weeks. At each visit, @entity1 and healthy control subjects underwent routine ophthalmic examinations and measurements of corneal sensitivity and tear function (Schirmer test of tear quantity, tear film break-up time [BUT], @entity941 staining of the @entity267 ). All control subjects and a subgroup of @entity1 also underwent conjunctival impression cytology for assessment of @entity1544 and goblet cell density. The outcomes of interest were changes in corneal sensitivity, tear function, and impression cytology variables after 3 weeks of treatment with @entity13205 eye drops, both in @entity1 with @entity56 and between @entity1 and controls. RESULTS: At enrollment, the study included 46 eyes of 23 @entity1 (9 @entity1 , 14 @entity1 ; age range, 20-42 years) with @entity56 ; results were calculated based on the 21 @entity1 who completed the study. The control group consisted of 70 eyes of 35 healthy subjects (13 @entity1 , 22 @entity1 ; age range, 22-39 years). Before treatment, 64.3% of the eyes of @entity1 with @entity56 had a @entity941 staining score of >1 point, whereas after treatment, 14.3% had a score of >1 point (P < 0.001). @entity1 ' mean (+/- SD) corneal sensitivity improved to 55.0 +/- 2.5 mm from the pretreatment value of 42.5 +/- 2.5 mm (P < 0.001). Mean BUT values before and after treatment were 8.1 +/- 3.5 and 14.0 +/- 7.0 seconds, respectively (P < 0.001). Before treatment, @entity1 ' mean @entity1544 grade was 2.5 +/- 0.5; at the end of treatment, it had decreased to 1.0 +/- 0.5 (P < 0.001). The mean pretreatment goblet cell density of 545 +/- 85 cells/ @entity202 improved to 1,090 +/- 100 cells/ @entity202 after treatment (P < 0.001). CONCLUSION: In the @entity1 population studied, the @entity121 , @entity1544 , and loss of ocular surface goblet cells associated with @entity56 improved with topical @entity13205 treatment.
